cancer weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of cancer weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Drug-discovery alliance enters phase I clinical trials in cancer
December 14th, 2004
Isis Pharmaceuticals, Inc., (ISIS) announced that LY2181308, the first antisense drug to emerge from its drug-discovery alliance with Eli Lilly and Co. (LLY), has moved into phase I clinical trials in cancer patients, marking a significant milestone in the partnership. For the accomplishment of this milestone, Isis earned a $1.5 million payment from Lilly. This is the second milestone Isis has achieved in the development of this second-generation antisense drug, which was licensed to Lilly in April 2003, and the third milestone achieved in the collaboration overall. Recently, Isis announced that Lilly licensed a second anticancer drug, LY2275796, for clinical...
Source: cancer weekly (2004-12-14)
|
